Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.1
4.9
Journals
IJMS
Special Issues
Molecular Aspects of Hematological Malignancies and Benign Hematological Disorders—3rd Edition
ijms-logo
Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Molecular Aspects of Hematological Malignancies and Benign Hematological Disorders—3rd Edition

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Biology".

Deadline for manuscript submissions: 20 June 2025 | Viewed by 3272

Special Issue Editor

Prof. Dr. Amelia Maria Găman

E-Mail Website
Guest Editor
1. Department of Pathophysiology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
2. Clinic of Hematology, Filantropia City Hospital, 200143 Craiova, Romania
Interests: hematology; internal medicine; pathophysiology; modern methods of teaching
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Hematological malignancies are complex disorders characterized by a complex molecular basis. The study and current understanding of their pathogenesis have been made possible by the recent advances in laboratory techniques such as molecular biology, flow cytometry, cytogenetics, pathology, and immunohistochemistry (to name a few), all of which have enabled the discovery and implementation of targeted therapies in the management of these peculiar disorders. This Special Issue aims to provide an insight into the molecular aspects of blood cancers as well as their impact on the diagnosis, evolution, and management of hematological malignancies. The submission of preclinical and translational research articles, as well as narrative and systematic reviews, is greatly encouraged.

Prof. Dr. Amelia Maria Găman
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • myeloproliferative neoplasms
  • leukemia
  • lymphoma
  • multiple myeloma
  • oxidative stress
  • inflammation
  • microbiome
  • genetics
  • molecular biology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

14 pages, 11842 KiB  
Article
Nidogen-1, a Player in KMT2A-Rearranged Pediatric Acute Myeloid Leukemia
by Jolien Vanhooren, Larissa Deneweth, Luca Pagliaro, Zhiyao Ren, Mariateresa Giaimo, Rafaella Zamponi, Giovanni Roti, Barbara Depreter, Mattias Hofmans, Barbara De Moerloose and Tim Lammens
Int. J. Mol. Sci. 2025, 26(7), 3011; https://doi.org/10.3390/ijms26073011 - 26 Mar 2025
Viewed by 291
Abstract
Despite advances in outcome, one third of children with acute myeloid leukemia (AML) relapse, and less than half will achieve long-term survival. Relapse in AML has been shown to be driven in part by leukemic stem cells (LSCs), highlighting the unmet medical need [...] Read more.
Despite advances in outcome, one third of children with acute myeloid leukemia (AML) relapse, and less than half will achieve long-term survival. Relapse in AML has been shown to be driven in part by leukemic stem cells (LSCs), highlighting the unmet medical need to better characterize and target this therapy-resistant cell population. Micro-array profiling of pediatric AML subpopulations (LSCs and leukemic myeloblasts) and their healthy counterparts revealed nidogen-1 (NID1) as expressed in both leukemic subpopulations while absent in the hematopoietic stem cell. Using the TARGET dataset including pediatric AML patients (n = 1025), NID1 expression showed a correlation with worse event-free survival and KMT2A rearrangements. Drug response profiling of a NID1 knockdown model demonstrated differential sensitivity to HSP90 inhibition. RNA sequencing and gene set enrichment analysis between NID1high and NID1low phenotypes showed involvement of NID1 in mitochondrial metabolic pathways known to be enriched in LSCs. Altogether, this study highlights NID1 as a novel oncogene associated with worse EFS and metabolic LSC phenotype in AML. NID1 could serve as a biomarker and aid in further mapping LSCs to establish therapeutic strategies tackling the high relapse rates in pediatric AML. Full article
(This article belongs to the Special Issue Molecular Aspects of Hematological Malignancies and Benign Hematological Disorders—3rd Edition)
►▼ Show Figures

Figure 1

14 pages, 1964 KiB  
Article
High Ki-67 Expression Predicting a Risk Factor for the Progression of Disease within 24 Months and Microenvironment in Follicular Lymphoma
by Hinako Narita, Kai Kuroiwa, Yukiko Kawaguchi, So Murai, Yosuke Sasaki, Mayumi Homma, Natsuki Kawamata, Hidenori Hayashi, Kazuki Nagao, Reiko Okamura, Yuka Uesugi, Yohei Sasaki, Shotaro Shimada, Megumi Watanuki, Nana Arai, Kouji Yanagisawa, Eisuke Shiozawa, Toshiko Yamochi and Norimichi Hattori
Int. J. Mol. Sci. 2024, 25(20), 11057; https://doi.org/10.3390/ijms252011057 - 15 Oct 2024
Cited by 1 | Viewed by 1083
Abstract
Most follicular lymphomas (FLs) demonstrate an indolent clinical course with favorable outcomes; however, a fraction of patients experiences progression of disease within 24 months (POD24) and has adverse outcomes. This study aimed to determine the predictive risk factors for POD24 in patients with [...] Read more.
Most follicular lymphomas (FLs) demonstrate an indolent clinical course with favorable outcomes; however, a fraction of patients experiences progression of disease within 24 months (POD24) and has adverse outcomes. This study aimed to determine the predictive risk factors for POD24 in patients with FL, and the characteristics of the microenvironment in FL with POD24. By multivariate analysis, we revealed that increased Ki-67 expression was associated with POD24 events in patients with FL (hazard ratio [HR]: 6.29, 95% confidence interval [CI]: 1.96–20.22, p = 0.0020). Additionally, patients with FL with POD24 demonstrated immune cell reduction by immunohistochemistry analysis. Our results help better understand the therapeutic strategies for FL with POD24. Full article
(This article belongs to the Special Issue Molecular Aspects of Hematological Malignancies and Benign Hematological Disorders—3rd Edition)
►▼ Show Figures

Figure 1

Review

Jump to: Research

20 pages, 1376 KiB  
Review
Notch Inhibitors and BH3 Mimetics in T-Cell Acute Lymphoblastic Leukemia
by Ilaria Sergio, Claudia Varricchio, Federica Squillante, Noemi Martina Cantale Aeo, Antonio Francesco Campese and Maria Pia Felli
Int. J. Mol. Sci. 2024, 25(23), 12839; https://doi.org/10.3390/ijms252312839 - 29 Nov 2024
Viewed by 1387
Abstract
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy with poor response to conventional therapy, derived from hematopoietic progenitors committed to T-cell lineage. Relapsed/Refractory patients account for nearly 20% of childhood and 45% of adult cases. Aberrant Notch signaling plays a critical [...] Read more.
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy with poor response to conventional therapy, derived from hematopoietic progenitors committed to T-cell lineage. Relapsed/Refractory patients account for nearly 20% of childhood and 45% of adult cases. Aberrant Notch signaling plays a critical role in T-ALL pathogenesis and therapy resistance. Notch inhibition is a promising therapeutic target for personalized medicine, and a variety of strategies to prevent Notch activation, including γ-secretase (GS) inhibitors (GSIs) and antibodies neutralizing Notch receptors or ligands, have been developed. Disruption of apoptosis is pivotal in cancer development and progression. Different reports evidenced the interplay between Notch and the anti-apoptotic Bcl-2 family proteins in T-ALL. Although based on early research data, this review discusses recent advances in directly targeting Notch receptors and the use of validated BH3 mimetics for the treatment of T-ALL and their combined action in light of current evidence of their use. Full article
(This article belongs to the Special Issue Molecular Aspects of Hematological Malignancies and Benign Hematological Disorders—3rd Edition)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop